This observation, however, contrasts with a recent report in which only the 1100delC variant and not overall CHEK2 mutations were enriched in lethal PCa patients [31], and therefore requires further validation in independent cohorts. The gene discussed is CHEK2; the disease is posterior cortical atrophy.